Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has conducted an inspection at Company's Solid Oral Oncology facility located at Panelav from 24 June, 2019 to 28 June, 2019. This was a first scheduled inspection and Company passed the inspection without any Form 483 Observation.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
